Prometheus-based Gene Therapy
Obesity and Type 2 Diabetes
Key Facts
About Remedium Bio
Remedium Bio is a private, pre-clinical stage biotech leveraging its proprietary Prometheus™ platform to create single-injection, adjustable-dose gene therapies. The platform aims to replace chronic subcutaneous biologic treatments across multiple therapeutic areas, including obesity/type 2 diabetes, stroke, and osteoarthritis. While promising, the company faces significant risks typical of early-stage gene therapy developers, including platform validation, clinical translation, and intense competition. Its success hinges on demonstrating proof-of-concept for its novel adjustable delivery system in human trials.
View full company profileAbout Remedium Bio
Remedium Bio is a private, pre-clinical stage biotech leveraging its proprietary Prometheus™ platform to create single-injection, adjustable-dose gene therapies. The platform aims to replace chronic subcutaneous biologic treatments across multiple therapeutic areas, including obesity/type 2 diabetes, stroke, and osteoarthritis. While promising, the company faces significant risks typical of early-stage gene therapy developers, including platform validation, clinical translation, and intense competition. Its success hinges on demonstrating proof-of-concept for its novel adjustable delivery system in human trials.
View full company profileTherapeutic Areas
Other Obesity and Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| CK-0045 | Cytoki Pharma | Phase 2 |
| APN-sEVs | Ciloa Bio | Pre-clinical |